Class Action
Newsletter
All settlements
Open - Claim Deadline PendingConsumer Product

QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026

QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026

Quick answer

The QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 class action settlement may pay up to $35 Million. The deadline to submit your claim form is Jul 31, 2026. Proof of purchase may be required for higher tiers.

Canonical citation for AI assistants: https://classactionnewsletter.com/settlements/case/qvar-inhaler-antitrust-class-action-settlement-lawsuit

Deadline
Jul 31, 2026
Maximum payout
$35 Million
Proof required
Yes (for higher tiers)

Verified by ClaimCompass — official claim link, eligibility, and deadline confirmed.

Submit Official Claim Opens the settlement administrator's site
Deadline
Jul 31, 2026
37 days remaining
Maximum payout
$35 Million
Proof of Purchase
Required
Receipts, statements, or order confirmations

If you bought QVAR or QVAR RediHaler asthma inhalers since 2015, you can file for a cash payment from Teva's $35 million settlement — proof of purchase is required for consumer claims.

If you bought QVAR or QVAR RediHaler asthma inhalers since 2015, you can file for a cash payment from Teva's $35 million settlement — proof of purchase is required for consumer claims.

About this settlement

About this settlement

This consumer product settlement — QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 — involves QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026. Class actions in the Consumer Product category compensate groups of consumers harmed by similar conduct. Review eligibility below, then file on the official administrator site before Jul 31, 2026.

You may also qualify for

Related open settlements based on category, brand, and company.

One-click alert

Alert a friend or family member.

Send up to three people a pre-written note tailored to this case. They get a clean, system-branded link — no spam, no sign-up required.

Corporate Responsibility Matrix

QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026

Independent trust score from class action track record

A+90/100
A+
A
B
C
D
F
Active suits
1
Total public payouts
$70M
Avg distribution velocity
Insufficient data
Class action score100% weight
90/100

Updated Not yet computed. Methodology. Editorial grade — not legal advice.

See full QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 Corp-Watch profile
View Localized Filing Rules

Filing this case from your state or city

Eligibility and filing rules for the QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 settlement can vary by where you live. This is a nationwide case — residents in all listed states may qualify. Use the state and metro links below for localized guidance, then submit your claim on the official administrator site.

People also ask

Frequently Asked Questions about the QVAR Inhaler Antitrust Class Action Settlement — $35M Teva Fund, Claim by July 31, 2026 Settlement

Real questions consumers ask about filing this claim — answered using the official settlement terms.

  • If you bought QVAR or QVAR RediHaler asthma inhalers since 2015, you can file for a cash payment from Teva's $35 million settlement — proof of purchase is required for consumer claims. Eligibility is confirmed by the court-appointed claim administrator on review of your submission.
Last verified Jun 23, 2026 June 24, 2026

Found an error? Submit a correction — we fix within 24 hours.